The University of Minnesota Medical School researchers today published the results from the first randomized clinical trial testing hydroxychloroquine versus a placebo for the post-exposure prevention of COVID-19. The study’s Dr. David Boulware says “what the trial showed is unfortunately that the hydroxychloroquine did not have a preventative effect and so that was basically about 12% of the people with hydroxychloroquine got COVID and 14% in the placebo group and that was not a statistical difference.” The study showed 40-percent of trial participants taking hydroxychloroquine developed non-serious side effects-—mainly nausea and upset stomach or diarrhea. The drug was tested in a double-blind trial, meaning that neither the participants nor the researchers knew what the participants received. Here’s more with Dr. Boulware: